Clinical trial · Observational
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patients with cancer. The investigators hypothesize that the detection of certain miRNAs present in the blood/serum of patients with pancreatic cancer may be important to the early diagnosis of the disease. Furthermore, the investigators hypothesize that miRNA detection in PC patients will yield prognostic information and help predict the response to treatment.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer Stage III | Malignant Pancreatic Neoplasm | CURATED_BROADER | 0.78 |
| Pancreatic Cancer Stage IV | Malignant Pancreatic Neoplasm | CURATED_BROADER | 0.78 |
| Pancreatic Ductal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Pancreatic Neoplasms | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood draw | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- New Unresectable Pancreatic Cancer
- description
- Individuals with biopsy-proven adenocarcinoma of the pancreas, classified as locally advanced or metastatic disease
- interventionNames
- Procedure: Blood draw
- label
- Control
- description
- Healthy individuals without cancer diagnoses to provide reference microRNA
- interventionNames
- Procedure: Blood draw
Primary outcomes (1)
- measure
- Analysis of miRNA profile
- timeFrame
- Through study completion, up to 5 years
- description
- Analyze the miRNA profiles present at each time point.
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Have biopsy proven adenocarcinoma of the pancreas * Have initially inoperable disease, classified as either locally advanced or metastatic disease * Recurrent disease after a Whipple procedure is allowed * Patients who are able to undergo resection after neoadjuvant therapy will continue to be followed after resection * Have radiographically measurable disease * Have an ECOG performance status of 2 or less * Be willing to contribute the required information and specimens * Provide written signed consent to participate Exclusion Criteria: * Having received prior anti-cancer treatments for metastatic pancreatic cancer * Concurrently receiving systemic therapy for another cancer except androgen deprivation therapy for stable/controlled prostate cancer * Presence of other active cancer except for: adequately treated local basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for \>1 year prior to start of trial. Other adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for \> 5 years is allowable
References
Publications (0)
Data not yet available